India has become one of the first countries to launch Awiqli (icodec insulin), the world's first weekly basal insulin for adults with diabetes.Developed by Novo Nordisk, this treatment reduces insulin injections from 365 to just 52 per year, offering blood sugar control comparable to daily basal insulin.The weekly insulin pen starts at ₹2,611.

Patients starting insulin therapy generally need about 10 units per day.With Awiqli, the same weekly requirement of approximately 70 units is administered through a single injection instead of seven daily doses.

The larger 2,100-count 3ml FlexTouch pen is priced at ₹7,833.